

Customer No.: 20462  
Confirmation No.: 9816  
Attorney Docket No. PU60782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jin, et al. Date: 27 February 2010  
Serial No.: 10/598,750 Group Art Unit No.: 1624  
Filed: 11 March 2005 Examiner: Unknown  
For: Novel M3 Muscarinic Acetylcholine Receptor Antagonists


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)

Sir:

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



/

/

Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017  
Facsimile (610) 270-5090